The new rule would prevent Florida minors from receiving puberty blockers, hormone therapy or surgeries as treatment for gender dysphoria.
The board is slated to meet again Nov. 4 to discuss the proposed rule. Once drafted, the board would launch a 28-day approval process that includes time for public comments.
Florida’s efforts to restrict gender-affirming care date back to April, when the health department released guidance recommending against nonurgent care. In August, Florida’s Medicaid regulator also finalized rules banning healthcare providers from billing Medicaid for gender-affirming medical treatment.
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
